Hypomethylating agents like azacitidine and decitabine have shown increased efficacy in managing TET2-mutant myeloid malignancies [59,60], while high-dose vitamin C can limit the expansion of hematopoietic stem and progenitor cells (HSPCs) with TET2 deletions [61]. Here, TET2 is linked to myeloid neoplasm.